Human medicines European public assessment report (EPAR): Increlex, mecasermin, Date of authorisation: 02/08/2007, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Increlex, mecasermin, Date of authorisation: 02/08/2007, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 17, Status: Authorised

Quarterly System Demo - Q1 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2026, 09:00 (CET) to 26 March 2026, 12:45 (CET)

Quarterly System Demo - Q1 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2026, 09:00 (CET) to 26 March 2026, 12:45 (CET)

EnprEMA & ACT EU workshop on paediatric clinical trials, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2026, 10:00 (CEST) to 12 May 2026, 17:00 (CEST)

EnprEMA & ACT EU workshop on paediatric clinical trials, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2026, 10:00 (CEST) to 12 May 2026, 17:00 (CEST)

PCWP/HCPWP joint meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 June 2026, 09:15 (CEST) to 1 July 2026, 12:00 (CEST)

PCWP/HCPWP joint meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 June 2026, 09:15 (CEST) to 1 July 2026, 12:00 (CEST)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.